[{"data":1,"prerenderedAt":267},["ShallowReactive",2],{"site":3,"legal-privacy":167},{"id":4,"aboutHeadline":5,"aboutIntro":6,"aboutLabel":7,"contactBody":8,"contactCta":9,"contactHeadline":12,"contactLabel":13,"designations":14,"designationsHeadline":22,"designationsLabel":23,"extension":24,"focusAreas":25,"focusHeadline":35,"focusLabel":36,"footerColumns":37,"footerCopyright":70,"footerLegalBlocks":71,"footerLegalLinks":81,"footerLogoMain":91,"footerLogoSub":92,"footerTagline":93,"heroEyebrow":94,"heroPrimaryCta":95,"heroSecondaryCta":97,"heroStats":99,"heroSubtitle":109,"heroTitle":110,"marqueeItems":111,"meta":120,"missionCallout":121,"missionHeadline":122,"missionLabel":96,"missionParagraphs":123,"navCta":126,"navLinks":128,"pipelineHeadline":137,"pipelineLabel":138,"pipelineNote":139,"pipelineStages":140,"seoDescription":162,"seoOgImage":163,"seoTitle":164,"stem":165,"__hash__":166},"site\u002Fsite\u002Findex.yml","The team behind\n*the science.*\n","ZP5 Therapeutics was co-founded by two industry veterans who previously built and sold a company together — bringing decades of combined experience in drug development, regulatory affairs, and clinical pharmacology to one of global health's most pressing problems.","About Us","Whether you're a potential partner, researcher, or investor, we'd love to share what we're working on and explore how we might work together toward better treatments for neglected diseases.",{"label":10,"href":11},"Reach Out","#contact","Want to learn more about\nZero Point Five Therapeutics?\n","Get In Touch",[15,19],{"tag":16,"title":17,"body":18},"FDA Designation","Rare Pediatric Disease Designation","Granted by the FDA in recognition of the serious and life-threatening nature of the condition in patients aged 18 and under. This designation provides eligibility for a Priority Review Voucher upon approval — a significant commercial and humanitarian milestone.",{"tag":16,"title":20,"body":21},"Orphan Drug Designation","Awarded by the FDA's Office of Orphan Products Development for our lead therapeutic candidate. This designation confers seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and waiver of the Prescription Drug User Fee Act application fee.","Recognized at every level\nof *regulatory priority.*\n","Regulatory Designations","yml",[26,29,32],{"title":27,"body":28},"Neglected Tropical Diseases","Targeting parasitic and bacterial infections that afflict hundreds of millions in tropical and subtropical regions with limited access to existing treatments.",{"title":30,"body":31},"Rare & Orphan Conditions","Addressing conditions that affect small patient populations, where the commercial incentive has historically been insufficient to attract pharmaceutical investment.",{"title":33,"body":34},"Drug-Resistant Infections","Developing novel therapeutic strategies to combat the global threat of antimicrobial resistance, which disproportionately impacts resource-limited healthcare settings.","Where our *science* is directed.","Focus Areas",[38,54,62],{"heading":39,"links":40},"Company",[41,44,46,49,52],{"label":42,"href":43},"Mission","#mission",{"label":36,"href":45},"#focus",{"label":47,"href":48},"Pipeline","#approach",{"label":50,"href":51},"Designations","#designations",{"label":53,"href":11},"Contact",{"heading":55,"links":56},"Regulatory",[57,58,59],{"label":17,"href":51},{"label":20,"href":51},{"label":60,"href":61},"ClinicalTrials.gov","https:\u002F\u002Fclinicaltrials.gov",{"heading":53,"links":63},[64,67],{"label":65,"href":66},"contact@zeropointfivetherapeutics.com","mailto:contact@zeropointfivetherapeutics.com",{"label":68,"href":69},"zeropointfivetherapeutics.com","https:\u002F\u002Fzeropointfivetherapeutics.com","© 2026 Zero Point Five Therapeutics, Inc. · All Rights Reserved",[72,75,78],{"heading":73,"body":74},"Forward-Looking Statements","This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development, regulatory strategy, and potential commercialization of Zero Point Five Therapeutics, Inc.'s product candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks related to clinical trial outcomes, regulatory review and approval, manufacturing, competition, and market conditions. Forward-looking statements speak only as of the date on which they are made, and Zero Point Five Therapeutics, Inc. undertakes no obligation to update or revise any forward-looking statement, except as required by law.",{"heading":76,"body":77},"Regulatory & Clinical Disclaimer","Zero Point Five Therapeutics, Inc.'s lead product candidate is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication. The safety and efficacy of this investigational compound have not been established. Rare Pediatric Disease Designation and Orphan Drug Designation are granted by the FDA and are not a guarantee of regulatory approval. These designations provide certain development incentives but do not confirm that the product candidate will receive marketing approval or be commercially successful. Information on this website is intended for informational purposes only and does not constitute medical advice, a solicitation for investment, or an offer to sell securities.",{"heading":79,"body":80},"No Offer of Securities","Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities of Zero Point Five Therapeutics, Inc. Any offering of securities will be made only pursuant to a formal offering memorandum or other applicable disclosure document in compliance with applicable federal and state securities laws.",[82,85,88],{"label":83,"href":84},"Privacy Policy","\u002Flegal\u002Fprivacy",{"label":86,"href":87},"Terms of Use","\u002Flegal\u002Fterms",{"label":89,"href":90},"Cookie Policy","\u002Flegal\u002Fcookies","Zero Point Five","Therapeutics, Inc.","Developing safe and efficacious treatments\nfor neglected diseases.","Phase 3 Clinical Stage",{"label":96,"href":43},"Our Mission",{"label":98,"href":11},"Get in Touch",[100,103,106],{"number":101,"label":102},"1B+","NTD-Affected People",{"number":104,"label":105},"2B","STH Infections Worldwide",{"number":107,"label":108},"149","Countries with Endemic NTDs","Zero Point Five Therapeutics, Inc. is developing safe and efficacious therapeutic interventions for diseases that have been historically overlooked by mainstream medicine.","Treatments for *neglected* diseases.",[112,113,114,115,116,117,118,119],"Phase 3 Clinical Trial","Safe & Efficacious","Neglected Diseases","Drug Discovery","Global Health","Novel Therapeutics","Patient-First Science","Zero Point Five Therapeutics",{},"\"Developing safe and efficacious treatments for neglected diseases is not just a scientific challenge — it is a moral imperative.\"","Science in service of the *overlooked*.",[124,125],"Neglected diseases disproportionately affect billions of people in low- and middle-income communities, yet they receive a fraction of global pharmaceutical research and development investment. The gap between need and resource is one of the most pressing inequities in modern medicine.","At Zero Point Five Therapeutics, Inc., we are committed to closing that gap — and we have moved beyond early research to the frontlines of clinical validation. Our lead program is now in Phase 3 clinical trials, combining rigorous scientific methodology with a genuine moral urgency to deliver therapeutic solutions that are both safe and highly effective for populations that have been left behind.",{"label":127,"href":11},"Learn More",[129,130,131,132,133,136],{"label":42,"href":43},{"label":36,"href":45},{"label":47,"href":48},{"label":50,"href":51},{"label":134,"href":135},"About","#about",{"label":53,"href":11},"Phase 3. *The final mile.*","Clinical Pipeline","Lead program currently enrolling in Phase 3 pivotal trial across multiple international clinical sites.",[141,145,148,151,155,159],{"label":142,"sublabel":143,"status":144},"Preclinical","Target ID & Lead Opt.","done",{"label":146,"sublabel":147,"status":144},"Phase 1","Safety & PK",{"label":149,"sublabel":150,"status":144},"Phase 2","Proof of Concept",{"label":152,"sublabel":153,"status":154},"Phase 3","Pivotal Trial","active",{"label":156,"sublabel":157,"status":158},"NDA \u002F BLA","Regulatory Filing","future",{"label":160,"sublabel":161,"status":158},"Approval","Market Access","Zero Point Five Therapeutics is developing safe and efficacious therapeutic interventions for neglected tropical diseases, rare & orphan conditions, and drug-resistant infections. Lead program currently in Phase 3.","\u002Fog\u002Fdefault.jpg","ZP5 Therapeutics — Treatments for Neglected Diseases","site\u002Findex","8OfwCKyQgTg28kv-Q_sWpvKqaqTTJpvjGzEKQxRJKUY",{"id":168,"title":83,"body":169,"description":250,"extension":260,"lastUpdated":261,"meta":262,"navigation":263,"path":84,"seo":264,"stem":265,"__hash__":266},"legal\u002Flegal\u002Fprivacy.md",{"type":170,"value":171,"toc":249},"minimark",[172,183,188,191,195,217,221,224,228,231,235,242,246],[173,174,175],"blockquote",{},[176,177,178,182],"p",{},[179,180,181],"strong",{},"Placeholder"," — this page contains template language and has not been reviewed by counsel. Replace before launch.",[184,185,187],"h2",{"id":186},"overview","Overview",[176,189,190],{},"Zero Point Five Therapeutics, Inc. (\"ZP5\", \"we\", \"us\") respects your privacy. This\npolicy describes what information we collect when you visit zeropointfivetherapeutics.com,\nhow we use it, and the choices you have.",[184,192,194],{"id":193},"information-we-collect","Information we collect",[196,197,198,205,211],"ul",{},[199,200,201,204],"li",{},[179,202,203],{},"Contact form submissions."," When you submit our contact form, we collect the name,\nemail address, organization, and message you provide.",[199,206,207,210],{},[179,208,209],{},"Anonymous analytics."," We use Cloudflare Web Analytics, which does not use cookies\nand does not track individual visitors across sites. Aggregated information about\npageviews, referrers, and devices may be retained.",[199,212,213,216],{},[179,214,215],{},"Server logs."," Standard request metadata (IP address, timestamp, requested URL,\nuser agent) may be retained briefly for operational and security purposes.",[184,218,220],{"id":219},"how-we-use-it","How we use it",[176,222,223],{},"We use submitted contact information solely to respond to your inquiry. We do not\nsell, rent, or share your information with third parties for marketing purposes.",[184,225,227],{"id":226},"how-long-we-keep-it","How long we keep it",[176,229,230],{},"Contact form submissions are retained in the recipient's email inbox under our\nstandard retention practices. Server logs are retained for no longer than 30 days.",[184,232,234],{"id":233},"your-rights","Your rights",[176,236,237,238,241],{},"If you would like to know what personal information we hold about you, request a\ncopy, or ask us to delete it, contact us at\n",[239,240,65],"a",{"href":66},".",[184,243,245],{"id":244},"changes-to-this-policy","Changes to this policy",[176,247,248],{},"We may update this policy from time to time. The effective date at the top of this\npage indicates when it was last revised.",{"title":250,"searchDepth":251,"depth":252,"links":253},"",2,3,[254,255,256,257,258,259],{"id":186,"depth":251,"text":187},{"id":193,"depth":251,"text":194},{"id":219,"depth":251,"text":220},{"id":226,"depth":251,"text":227},{"id":233,"depth":251,"text":234},{"id":244,"depth":251,"text":245},"md","2026-04-21",{},true,{"title":83,"description":250},"legal\u002Fprivacy","ntDaHpEhcAQi8pD0GS3aBCHubsAZn1uUrovTnQy-AB4",1777662005157]